Jacobs Levy Equity Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Jacobs Levy Equity Management’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15,200	Closed	-$36K	–	913
2015 Q2	$36K	Buy	+15,200	New	+$46.9K	﹤0.01%	791

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Jacobs Levy Equity Management's TLOG Position: Q3 2015 in Review

Jacobs Levy Equity Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2015, closing a stake of 15,200 shares — an estimated $36K sold.

Jacobs Levy Equity Management first reported a position in TLOG in Q2 2015 and held it in 1 quarter. The position peaked at $36K in Q2 2015. 29 funds tracked by Wall St. Rank hold TLOG as of Q3 2015.

Jacobs Levy Equity Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2015 after selling out during the quarter.
Jacobs Levy Equity Management sold 15,200 TetraLogic Pharmaceuticals Corporation shares in Q3 2015, an estimated $36K.
Jacobs Levy Equity Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2015 and held it in 1 quarter.
Jacobs Levy Equity Management's TetraLogic Pharmaceuticals Corporation position peaked at $36K in Q2 2015.
29 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2015.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2015, filed 16 Nov 2015.